Safety, Tolerability, and PK/PD of CIGB-814 in Chinese Health Participants

NCT07182656 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis (RA)

Interventions

DRUG: CIGB-814 (single-dose group)
DRUG: CIGB-814 placebo (single-dose group)
DRUG: CIGB-814 (multiple-dose group)
DRUG: CIGB-814 placebo (multiple-dose group)

Sponsor

Yi Fang